Ohio State Navbar

Directory

William Blum, MD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 293-9869

Email: blum.51@osu.edu

 

Current OSU Appointments

Associate Professor, Hematology

Physician, FGP-Hematology

 

Clinical Interest

Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia (AML)

Academic Advising

In addition to my responsibilities in the Division of Hematology for our current fellows, I am help to select upcoming fellows and play a significant role in the recruitment and interviewing/selection of upcoming fellows who may have interest in careers in academic medicine, particularly from an active recruitment standpoint those applicants with interest in the area of my expertise. I serve also as a faculty member of the T32 training grant held by Drs. Villalona and Devine.

Academic Advising

2007 - present Alison Walker The Ohio State University.
2009 - present Alice Mims Medical University of Charleston South Caroloina. Graduated 2012.
2009 - present Jason Mendler University of Rochester Medical Center. Graduated 2012.
2012 - present Sumithira Vasu The Ohio State University.
2012 - present Katherine Walsh The Ohio State University.
2013 - present Karilyn Larkin The Ohio State University.
2008 - 2009 Jason Chandler The Ohio State University. Graduated 2009.
2010 - 2011 Jason Mendler The Ohio State University. Graduated 2011.
2012 - 2013 Kate Leininger The Ohio State University. Graduated 2014.
 

Certifications

2001 - present Board Certification in Internal Medicine: American Board of Internal Medicine
2003 - present Medical License: State Medical Board of Ohio
2004 - present Board Certification in Medical Oncology: American Board of Internal Medicine
2004 - present Board Certification in Hematology: American Board of Internal Medicine
 

Chapters in Books

Blum W, Picus J. "Prostate Cancer." In Govindan R, ed.. 383-393. Philadelphia: Lippincott, Williams, and Wilkins, January 2002.

 

Clinical Services

08/01/2003 Attending Physician (Acute Leukemia Service - Arthur G. James Cancer Hospital, Hematology and Oncology)
08/01/2003 Attending Physician (Ambulatory Marrow Transplant Unit Clinic - Arthur G. James Cancer Hospital, Hematology and Oncology)
08/01/2003 Attending Physician (Blood and Marrow Transplant Program - Arthur G. James Cancer Hospital, Hematology and Oncology)
08/01/2003 Attending Physician (Hematologic Malignancy Clinic - Arthur G. James Cancer Hospital, Hematology and Oncology)
01/01/2014 Disease Group Leader for Clinical Trials Office, AML and MDS (James)

Conferences

Brown RA, Adkins DR, Khoury H, Westervelt P, Goodnough L, Vij R, Blum W, DiPersio JF. "Mobilization of allogeneic PBSC with GM-CSF instead of G-CSF is associated with a reduced risk of acute graft-vs-host disease (GVHD)." In Blood. (November 2001). 737A-737A.

Khoury H, Adkins D, Pence H, Shenoy S, Blum W, Westervelt P, Vij R, Brown R, Goodnough L, DiPersio J. "Hydroxychloroquine for prevention of acute GVHD in unrelated donor (URD) transplantation: Effect on chronic GVHD and long-term survival." In Blood. (November 2001). 368B-368B.

Omotoso O, Khoury H, Adkins D, Blum W, Iregui M, Westervelt P, Vij R, Brown R, Goodnough L, DiPersio J. "Outcomes of stem cell transplant recipients requiring mechanical ventilation and cared for in the bone marrow transplant unit." In Blood. (November 2001). 350B-350B.

Blum W, Hallem C, Vij R, Shenoy S, Goodnough L, Brown R, Khoury H, Westervelt P, DiPersio J, Adkins D. "Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: Long-term follow-up." In Blood. (November 2001). 58A-58A.

Blum W, Brown RA, Khoury H, Lin HS, Vij R, Oza Y, Schultz P, Rearden T, Willis R, Naughton M, Goodnough LT, Westervelt P, DiPersio JF, Adkins DR. "Primary amyloidosis (AL) patients with significant organ dysfunction treated with conventional chemotherapy followed by single-dose total body irradiation (TBI) and autologous peripheral blood stem cell transplant (PBSC) the, IFN-alpha maintenance: Tolerance and efficacy." In Blood. (November 2001). 684A-684A.

Girgis M, Brown RA, Khoury H, Hallemeier C, Zehnbauer B, Goodnough LT, Westervelt P, Vij R, Blum W, Lin HS, DiPersio JF, Adkins DR. "Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplant (BMT) results in consistent donor cell engraftment without fatal regimen-related toxicity (RROT)." In Blood. (November 2001). 478A-479A.

Shenoy S, Hayashi R, Goodnough L, Khoury H, Brown R, Vij R, Blum W, DiPersio J, Adkins D. "Sustained improvement in post transplant NK cell function following donor derived G-CSF mobilized granulocyte transfusion in recipients of allogeneic peripheral blood stem cell transplants (SCT): Can this impact survival?." In Blood. (November 2001). 59A-59A.

Girgis M, Hallemeier C, Brown R, Khoury H, Zehnbauer B, Goodnough L, Westervelt P, Vij R, Blum W, Lin HS, DiPersio J, Adkins D. "Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) results in reduced non-relapse mortality (NRM) in comparison to standard TBI-based regimens." In Blood. (November 2001). 671A-671A.

Blum W, Girgis M, Hallemeier C, Vij R, Lin HS, Khoury H, Goodnouh LT, Devine S, DiPersio J, Brown R, Adkins D. "Outcomes for patients with non-Hodgkin's lymphoma following donor transplantation using low dose, single exposure total body irradiation and cyclophosphamide conditioning: A single institution experience." In Blood. (November 2002). 427A-427A.

Devine SM, Adkins DR, Khoury H, Vij R, Goodnough LT, Graubert T, Tomasson M, Blum W, DiPersio JF, Brown RA. "Mobilization of donors with GM-CSF plus G-CSF or GM-CSF alone results in significantly different graft composition compared to G-CSF alone." In Blood. (November 2002). 825A-825A.

Devine SM, Adkins DR, Khoury H, Vij R, Goodnough LT, Graubert T, Tomasson M, Blum W, DiPersio JF, Brown RA. "Impact of GM-CSF mobilization on the composition of donor allografts and the risk of acute GVHD following HLA-matched hematopoietic cell transplantation." In Blood. (November 2002). 175A-175A.

Hallemeier C, Girgis M, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, DiPersio J, Adkins D. "Low-dose (550 cGy), single-exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) for patients with acute myelogenous leukemia (AML) in complete remission (CR) results in reduced non-relapse mortality (NRM) and improved survival in comparison to standard TBI regimens." In Blood. (November 2002). 636A-637A.

Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, DiPersio J, Adkins D. "Low-dose (556 cGy), single-exposure total body irradiation (TBI) with cyclophosphamide as conditioning for 99 patients undergoing unrelated donor (URD) bone marrow transplantation (BMT) results in a graft failure rate (7.1%) comparable to that observed with standard TBI-based regimens." In Blood. (November 2002). 619A-620A.

Hallemeier C, Girgis M, Khoury H, Devine S, Blum W, Vij R, Lin HS, DiPersio J, Adkins D. "Similar outcomes in patients >= 50 years old and patients < 50 years old undergoing unrelated donor bone marrow transplantation following reduced intensity conditioning with single exposure (550 cGy) total body irradiation and cyclophosphamide." In Blood. (November 2003). 484A-484A.

Hallemeier C, Girgis M, Khoury H, Devine S, Blum W, Vij R, Lin HS, DiPersio J, Adkins D. "Allogeneic stem cell transplantation for 45 patients with myelodysplastic syndrome conditioned with an intermediate-intensity regimen of single exposure 550 cGy total body irradiation and cyclophosphamide." In Blood. (November 2003). 467A-467A.

Blum WG, Bolwell BJ, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. "Only those refractory AML patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation." In Blood. (November 2003). 488A-488A.

Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Vardiman JW, Larson RA, Bloomfield CD. "Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461." In Journal of Clinical Oncology. (July 2004). 568S-568S.

Copelan EA, Penza S, Lin T, Blum W, Farag S; Elder P, Avalos B. "Association between regimen related toxicity and acute-graft-versus-host disease." In Blood. (November 2004). 337B-337B.

Benson DM, Elder PJ, Lin T, Blum W, Penza S, Avalos B, Byrd JC, Copelan E, Farag SS. "Single institution experience with two high-dose chemotherapy (HDC) conditioning regimens prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM)." In Blood. (November 2004). 388B-389B.

Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B. "Matched unrelated transplantation in older individuals." In Blood. (January 2004). 480B-480B.

Blum W, Blum KA, Kefauver C, Moran M, Chan K, Byrd JC, Cataland S, Grever MR, Marcucci G. "Decitabine-induced differentiation syndrome in a patient with acute myeloid leukemia: A case report." In Blood. (November 2004). 215B-216B.

Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd JC, Elder P, Copelan EA. "Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens." In Blood. (November 2004). 364B-364B.

Marcucci G, Stock W, Dai G, Liu S, Klisovic R, Klisovic MI, Sher D, Huynh L, Franke S, Blum W, Larson RA, Grever MR, Byrd JC, Chan KK. "Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML)." In Blood. (November 2004). 331A-331A.

Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, DiPersio JF, Khoury HJ. "Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma." In Journal of Clinical Oncology. (November 2004). 4561-4566.

Blum W, Mrozek K, Maharry K, Raimondi SC, Carroll AJ, Larson RA, Rowley JD, Bloomfield CD. "Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23." In Journal of Clinical Oncology. (June 2005). 572S-572S.

Klisovic RB, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever MR, Marcucci G. "A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamic (PD) and clinical results." In Blood. (November 2005). 782A-783A.

Blum W, Bruner-Klisovic R, Liu SJ, Byrd JC, Liu ZF, Chan KK, Kefauver C, Huynh L, Grever MR, Marcucci G. "Phase I study of low dose decitabine in patients with acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity." In Blood. (November 2005). 529A-529A.

Marcucci G, Klisovic RB, Wei W, Liu S, Paschka P, Huynh L, Zwiebel JA, Byrd JC, Grever MR, Chan K, Blum W. "A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)." In Journal of Clinical Oncology. (June 2006). 352S-352S.

Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever MR, Marcucci G, Byrd JC. "Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics." In Journal of Clinical Oncology. (June 2006). 353S-353S.

Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Huynh LN, Liu S, Grever MR, Colevas AD, Marcucci G, Byrd JC. "Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD)." In Blood. (November 2006). 224B-224B.

Blum W, Marcucci G, Devine H, Klisovic R. "Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13)." In Blood. (November 2006). 181B-181B.

Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P, Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G. "Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells." In Blood. (November 2006). 132B-132B.

Crawford RD, Krugh D, Blum W, Devine S. "Transplantation without hemolysis in a kell antigen positive patient undergoing peripheral hematopoietic stem cell transplant from a donor with anti-kell antibodies." In Blood. (November 2006). 114B-114B.

Lynn DJ, Blum W, Cataland S, Rammohan KW. "Multiple sclerosis and mitoxantrone treatment-related leukemia: A single center experience." In Neurology. (March 2006). A31-A31.

Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu S, Liu Z, Chan KK, Plass C, Grever MR, Byrd JC, Marcucci G. "Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response." In Journal of Clinical Oncology. (June 2006). 340S-340S.

Sun J, Liu S, Yu J, Wei M, Mao C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic RB, Perrotti D, Chen C-S, Blum WG, Marcucci G. "Characterization of HDACI OSU42 as a novel histone deacetylase inhibitor in AML cell lines." In Blood. (November 2006). 563A-563A.

Ali NA, O'Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." In Cancer. (July 2007). 96-102.

Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." In Journal of Clinical Oncology. (September 2007). 3884-3891.

Blum W, Klisovic RB, Johnson A, Kefauver C, Phelps M, Lucas D, Huynh L, Liu S, Dalton JT, Grever MR, Marcucci G, Byrd JC. "Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule." In Blood. (November 2007). 272A-272A.

Hamadani M, Elder P, Awan F, Krugh D, Blum W, Lin T, Andritsos L, Bechtel T, Blum K, Klisovic R, Devine SM. "High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG." In Blood. (November 2007). 351B-351B.

Garzon R, Liu S, Fabbri M, Liu Z, Pang J, Muthusamy N, Blum W, Chan K, Byrd JC, Croce CM, Marcucci G. "MicroRNA (miRNA)-29b targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 genes in acute myeloid leukemia (AML)." In Blood. (November 2007). 220A-220A.

Wetzler M, Stock W, Donohue KA, Owzar K, Sher DA, Hoke EE, McCarty JM, Blum WG, Powell BL, Bloomfield CD, Linker CA, Larson RA. "Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001." In Blood. (November 2007). 843A-844A.

Blum WG, Andritsos LA, Johnson AJ, Klisovic RB, Kefauver C, Devine SM, Marcucci G, Byrd JC. "Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose." In Journal of Clinical Oncology. (May 2008). abstract 7074-.

Benson D, Andritsos L, Hamadani M, Lin T, Flynn J, Jones J, Blum W, Elder P, Lozanski G, Byrd J, Devine S. "Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation." In Blood. (November 2008). 1133-1134.

Hamadani M, Phillips G, Elder P, Yansak B, Blum W, Penza S, Lin TS, Farag SS, Devine SM. "Phase-II Study of Infliximab for the Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In Biology of Blood and Marrow Transplantation. (February 2008). 130-131.

Hamadani M, Blum KA, Elder P, Lin TS, Porcu P, Hofmeister CC, Blum W, Marcucci G, Benson D, Devine S. "Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas." In Blood. (November 2008). 1121-1121.

Blum W, Klisovic R, Liu S, Garzon R, Kefauver C, Liu Z, Mickle J, Devine H, Devine S, Grever MR, Chan KK, Villalona-Calero M, Byrd JC, Marcucci G. "Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)." In Blood. (November 2008). 1016-1016.

Andritsos L, Hamadani M, Heerema NA, Benson D, Hofmeister CC, Blum W, Flynn J, Jones JA, Elder P, Lin TS, Lozanski G, Byrd JC, Devine S. "Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)." In Blood. (November 2008). 756-757.

Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcucci G. "Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." In Blood. (November 2009). 1454-1455.

Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G. "Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." In Blood. (November 2009). 815-816.

Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, Andritsos L. "Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia." In Blood. (November 2009). 1339-1339.

DiPersio JF, Collins RH, Blum W, Devetten MP, Stiff P, Elias L, Reddy A, Smith JA, Khoury HJ. "Immune Responses in AML Patients Following Vaccination with GRNVAC1, Autologous RNA Transfected Dendritic Cells Expressing Telomerase Catalytic Subunit hTERT." In Blood. (November 2009). 262-262.

Hamadani M, Benson DM, Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T, Marcucci G, Blum W, Devine SM. "Evaluation of Rabbit Antithymocyte Globulin (RATG) Dose-Intensity in Patients Undergoing Allogenetic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and RATG (FBA)." In Biology of Blood and Marrow Transplantation. (February 2009). 5-5.

Blum WG, Klisovic R, Liu S, Kefauver C, Grever MR, Schaaf L, Chan K, Byrd JC, Villalona-Calero M, Marcucci G. "Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older." In Journal of Clinical Oncology. (May 2009). abstract 7010-.

Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang X, Schaaf L, Schwind S, Becker H, Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W. "Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." In Blood. (November 2009). 346-347.

Khoury HJ, Collins RH, Blum W, Maness L, Stiff P, Kelsey SM, Reddy A, Smith JA, DiPersio JF. "Prolonged Administration of the Telomerase Vaccine GRNVAC1 Is Well Tolerated and Appears to Be Associated with, Favorable Outcomes in High-Risk Acute Myeloid Leukemia (AML)." In Blood. (November 2010). 904-904.

Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum W, Booth A, Stone RM, Moser BK, Larson R. "Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502." In Blood. (November 2010). 150-150.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y-Z, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study." In Blood. (November 2010). 48-49.

Metzeler K, Maharry K, Margeson D, Curfman J, Becker H, Radmacher M, Mrozek K, Holland K, Whitman S, Wu Y, Schwind S, Blum W, Powell B, Carter T, Baer M, Carroll A, Kolitz J, Caligiuri M, Larson R, Marcucci G, Bloomfield C. "TET2 Mutation Occur on Over 20% of Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia, and their Prevalence Increases with Age: A Cancer and Leukemia Group B Study." In Haematologica-The Hematology Journal. (June 2010). 12-13.

Klisovic RB, Blum W, Chen P, Xie Z, Liu S, Walker A, Devine S, Garzon R, Byrd J, Wetzler M, Sayar H, Damon L, Grosskreutz C, Solomon S, Murray P, Chan K, Marcucci G. "A Phase II Study of GTI-2040, an Antisense to Ribonucleotide Reductase in Combination with High-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia." In Haematologica-The Hematology Journal. (June 2010). 27-27.

Blum W, Klisovic RB, Garzon R, Walker A, Schwind S, Liu S, Schaaf L, Garr C, Devine SM, Grever MR, Byrd JC, Marcucci G. "Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." In Blood. (November 2010). 1349-1349.

Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M, Kolitz JE, Wetzler M, Hoke E, Moser BK, Larson RA. "Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study." In Blood. (November 2010). 898-899.

Mendler JH, Maharry K, Radmacher MD, Mrozek K, Kohlschmidt J, Nicolet Deedra, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, Baer MR, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures." In Blood. (November 2011). 1476-1477.

Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Gibson LF, Remick SC, Leadmon S, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM, Devine SM. "Higher Busulfan Dose Intensity does not Improve Outcomes of Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT) following Fludarabine/Busulfan (FBA)-Based REduced Toxicity Conditioning (RTC)." In Biology of Blood and Marrow Transplantation. (February 2011). S306-S306.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y-Z, Blum W, Powel BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "Mutations in the TET Oncogene Family Member 2 (TET2) Gene Refine in the New European Leukemia Net Risk Classification of Primary, Cytogeinetically Normal Acute Myeloid Leukemia in Adults: A Cancer and Leukemia Group B Study." In Annals of Hematology. (February 2011). S8-S8.

Huang X, Schwind S, Yu B, Pang J, Santhanam R, Chan KK, Garzon R, Blum W, Bloomfield CD, Liu S, Perrotti D, Lee RJ, Byrd JC, Muthusamy N, Lee LJ, Marcucci G. "Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)." In Blood. (November 2011). 39-39.

Walker AR, Metzeler KH, Geyer S, Becker H, Schwind S, Whitman SP, Curfman J, Wu Y-Z, Perrotti D, Klisovic RB, Garzon R, Blum W, Marcucci G. "Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)." In Blood. (November 2011). 430-430.

Edwards CG, Maharry K, Mrozek K, Schwind S, Paschka P, Nicolet D, Kohlschmidt J, Prior TW, Wu Y-Z, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. "Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)." In Blood. (November 2011). 1077-1077.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Uv V, Liu Z, Schwind S, Mims AS, Klisovic RB, Walker A, Grever MR, Villalona-Calero M, Byrd JC, Garzon R, Blum W, Chan KK, Marcucci G. "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)." In Blood. (November 2012). abstract 3578-.

Wetzler M, Watson D, Stock W, Owzar K, Koval G, Hoke E, McCarty JM, Blum W, Powell BL, Marcucci G, Bloomfield CD, Linker C, Larson RA. "Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance)." In Blood. (November 2012). abstract 816-.

Klisovic RB, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine SM, Wang J, Garr C, Norris A, Byrd JC, Grever MR, Blum W, Chan KK, Marcucci G. "Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results." In Blood. (November 2012). abstract 3616-.

Blum W, Sanford B, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wetzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA. "Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)." In Blood. (November 2012). abstract 44-.

Rodriguez BAT, Frankhouser D, Murphy M, Trimarchi M, Tam H-H, Curfman J, Huang R, Chan MWY, Lai H-C, Parikh D, Ball B, Schwind S, Blum W, Marcucci G, Yan P, Bundschuh R. "Methods for high-throughput MethylCap-Seq data analysis." In BMC Genomics. (October 2012). S14-.

Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. "Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." In Blood. (November 2012). abstract 1942-.

Devine SM, Owzar K, Blum W, DeAngelo D, Stone RM, Hsu JW, Champlin RE, Chen Y-BA, Vij R, Slack JL, Soiffer RJ, Larson RA, Shea TC, Hars V, Bennett E, Spangle S, Giralt SA, Carter SL, Horowitz MM, Linker C, Alyea EP. "A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502." In Blood. (November 2012). abstract 230-.

Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. "Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease." In Blood. (November 2012). abstract 1949-.

Blum W, Klisovic RB, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine SM, Walsh K, Vasu S, Curfman JP, Schaaf L, Garr C, Kefauver C, Byrd JC, Grever MR, Garzon R, Marcucci G. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine." In Blood. (November 2012). abstract 2619-.

Beumer JH, Lewis LD, Owzar K, Jiang C, Holleran JL, Christner SM, Blum WG, Devine SM, Kolitz JE, Linker CA, Larson RA, Ratain MJ, Egorin MJ. "Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study." In Journal of Clinical Oncology. (May 2012). abstract 2533-.

Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum WG, Marcucci G, Bloomfield CD, Moser BK, Stone RM, Larson RA. "A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.." In Journal of Clinical Oncology. (May 2012). 923-929.

Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. "Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)." In Blood. (November 2012). abstract 4192-.

Cohen JB, McBride A, Geyer S, Bingman A, Elder P, Blum W, Klisovic R, Penza S, Andritsos LA, Benson DM, Efebera Y, Hofmeister CC, Garzon R, Marcucci G, Devine SM. "Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics." In Biology of Blood and Marrow Transplantation. (February 2013). S320-S321.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y. "Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)." In Biology of Blood and Marrow Transplantation. (February 2013). S304-S305.

Pandit A, Wei L, Elder P, Falk W, Sell M, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y. "Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)." In Biology of Blood and Marrow Transplantation. (February 2013). S186-S186.

Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, Andritsos LA, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G. "Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)." In Biology of Blood and Marrow Transplantation. (February 2013). S202-S202.

Jiang Y, Wang J, Walker A, Li X, Drake A, Schaaf L, Byrd J, Marcucci G, Grever M, Blum W, Phelps M. "Lenalidomide Pharmacokinetics in Combination with Idarubion and Cytarabine in Patients with Acute Myeloid Leukemia." In Clinical Pharmacology & Therapeutics. (February 2013). S66-S67.

Bernot KM, Nemer JS, Santhanam R, Liu S, Marcucci GG, Zorko NA, Whitman SP, Yan P, Frankhouser D, Bundschuh R, Zhang M, Siebenaler RF, Ahmed EH, McConnell KK, Munoz M, Brook DL, Dorrance AM, Dickerson KE, Zhang X, Zhang J, Jarjoura D, Lee R, Blum W, Caligiuri MA, Marcucci G. "Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in MII-PTD/Flt3-ITD acute myeloid leukemia." In Cancer Research. (April 2013). abstract 3249-.

Tarighat SS, Mahasenan K, Perrotti D, Garzon R, Caligiuri M, Li C, Blum W, Marcucci G, Baiocchi RA. "Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia." In Cancer Research. (April 2013). abstract 1128-.

 

Degrees

1993 B.S., University of Notre Dame

1997 M.D., Medical College of Georgia

 

Editorial Activities

2003 British Journal of Hematology
2004 Annals of Hematology
2006 - present Cancer Chemotherapy and Pharmacotherapy
2006 - 2009 Haematologica
2007 - present Italian Association of Cancer Research
2007 - present Scandinavian Journal of Infectious Disease
2007 - present American Journal of Hematology
2009 - present Leukemia and Lymphoma
2010 - present Blood
2013 - present Journal of Clinical Oncology
2014 - present Journal of the National Comprehensive Cancer Network
 

Honors

2009 Service Award. College of Medicine Educational Programs.
2011 - 2014 Best Doctors in America. Best Doctors.
 

Journal Articles

Blum W. "Advances in Non-transplant therapy for Chronic Myelogenous Leukemia." The Fellow Reporter. Vol. 7, no. 4. (January 2002.): 44-48.

Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT, Westervelt P, Vij R, DiPersio J, Adkins D. "Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: Consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity." Biology of Blood and Marrow Transplantation. Vol. 8, no. 11. (January 2002.): 608-618.

Vij R, DiPersio J, Khoury H, Goodnough LT, Devine SM, Blum W, Adkins D. "Response: Granulocyte transfusions and cytomegalovirus infection." Blood. Vol. 101, no. 12. (June 2003.): 5092-5092.

Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goodnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D. "Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation." Blood. Vol. 101, no. 5. (March 2003.): 2067-2069.

Vij R, Khoury H, Brown R, Goodnough LT, Devine SM, Blum W, Adkins D, DiPersio JF. "Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation." Bone Marrow Transplantation. Vol. 32, no. 7. (October 2003.): 703-707.

Blum W, Khoury H, Lin HS, Vij R, Goodnough LT, Devine S, DiPersio J, Adkins D. "Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: A feasibility study." Biology of Blood and Marrow Transplantation. Vol. 9, no. 6. (June 2003.): 397-404.

Devine SM, Adkins DR, Khoury H, Brown RA, Vij R, Blum W, DiPersio JF. "Recent advances in allogeneic hematopoietic stem-cell transplantation." Journal of Laboratory and Clinical Medicine. Vol. 141, no. 1. (January 2003.): 7-32.

Chohan R, Vij R, Adkins D, Blum W, Brown R, Tomasson M, Devine S, Graubert T, Goodnough LT, DiPersio JF, Khoury H. "Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity." British Journal of Haematology. Vol. 123, no. 1. (October 2003.): 110-113.

Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD. "Adult de novo acute myeloid leukemia with t(6;11)(q27;q23) - Results from cancer and leukemia group B study 8461 and review of the literature." Cancer. Vol. 101, no. 6. (September 2004.): 1420-1427.

Hidalgo JD, Krone R, Rich MW, Blum K, Adkins D, Fan MY, Brown R, Devine S, Graubert T, Blum W, Tomasson M, Goodnough LT, Vij R, DiPersio J, Khoury H. "Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes." Bone Marrow Transplantation. Vol. 34, no. 7. (October 2004.): 615-619.

Hallemeier C, Girgis M, Blum W, Brown R, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Lin HS, Dipersio F, Adkins D. "Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure and total body irradiation, cyclophosphamide, unrelated donor bone marrow transplants." Biology of Blood and Marrow Transplantation. Vol. 10, no. 5. (May 2004.): 310-319.

Hoerr AL, Gao F, Hidalgo J, Tiwari D, Blum KA, Mathews V, Adkins DR, Blum W, Devine S, Vij R, Goodnough LT, DiPersio JF, Khoury HJ. "Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma." Journal of Clinical Oncology. Vol. 22, no. 22. (November 2004.): 4561-4566.

Marcucci G, Stock W, Dai GW, Klisovic RB, Liu SJ, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. "Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity." Journal of Clinical Oncology. Vol. 23, no. 15. (January 2005.): 3404-3411.

Girgis M, Hallemeier C, Blum W, Brown R, Lin HS, Khoury H, Goodnough LT, Vij R, Devine S, Wehde M, Postma S, Oza A, DiPersio J, Adkins D. "Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide." Blood. Vol. 105, no. 8. (April 2005.): 3035-3041.

Benson DM, O'Donnell L, Krugh D, Grady T, Blum W, Williams JD, Kennedy MS, Marcucci G. "Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis." Bone Marrow Transplantation. Vol. 36, no. 12. (December 2005.): 1111-1112.

Blum W, Marcucci G. "Targeting epigenetic changes in acute myeloid leukemia." Clinical Advances in Hematology & Oncology : H&O. Vol. 3, no. 11. (November 2005.): 855-865, 882.

Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. "High-dose busulfan, cyclophosphamide, and Etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia." Bone Marrow Transplantation. Vol. 35, no. 7. (April 2005.): 653-661.

Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin H-S, DiPersio JF, Adkins DR. "Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide." Biology of Blood and Marrow Transplantation. Vol. 12, no. 7. (July 2006.): 749-757.

Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. "High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation." Biology of Blood and Marrow Transplantation. Vol. 12, no. 1. (January 2006.): 61-67.

Wei X, Dai G, Marcucci G, Liu Z, Hoyt D, Blum W, Chan KK. "A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices." Pharmaceutical Research. Vol. 23, no. 6. (June 2006.): 1251-1264.

Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G. "Targeting AML1/ETO-histone deacetylase repressor complex: A novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells." Journal of Pharmacology and Experimental Therapeutics. Vol. 321, no. 3. (June 2007.): 953-960.

Ali NA, O'Brien JM, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." Cancer. Vol. 110, no. 1. (July 2007.): 96-102.

Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, Marcucci G, Chan KK. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS." Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. Vol. 850, no. 1-2. (May 2007.): 206-212.

Benson DM, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS. "High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma." Leukemia Research. Vol. 31, no. 8. (August 2007.): 1069-1075.

Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." Journal of Clinical Oncology. Vol. 25, no. 25. (September 2007.): 3884-3891.

Blum W, Marcucci G. "Hypomethylation Therapy in Acute Myeloid Leukemia." Cancer Investigation. Vol. 25, (January 2007.): 33-35.

Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Kilsovic R, Byrd JC, Chan KK, Marcucci G. "Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method." Nucleic Acids Research. Vol. 35, no. 5. (January 2007.): e31-.

Blum W, Porcu P. "Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome." Seminars in Thrombosis and Hemostasis. Vol. 33, no. 4. (June 2007.): 350-354.

Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, Evens A, Scheetz MH, Blum W, Kontoyiannis DP. "Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy." Bone Marrow Transplantation. Vol. 39, no. 7. (April 2007.): 425-429.

Hamadani M, Benson DM, Blum W, Garzon R, Devine SM. "Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease." Transplant Infectious Disease. Vol. 10, no. 1. (February 2008.): 24-26.

Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. "Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia." Clinical Cancer Research. Vol. 14, no. 12. (June 2008.): 3889-3895.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, MacLeod AR, Besterman JM, Reid GK, Byrd JC, Marcucci G. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia." Clinical Cancer Research. Vol. 14, no. 8. (April 2008.): 2444-2449.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu L-C, Marcucci G. "Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-{kappa}B-dependent DNA methyltransferase activity in acute myeloid leukemia." Blood. Vol. 111, no. 4. (February 2008.): 2364-2373.

Plass C, Oakes C, Blum W, Marcucci G. "Epigenetics in Acute Myeloid Leukemia." Seminars in Oncology. Vol. 35, no. 4. (August 2008.): 378-387.

Ramsay AG, Johnson AJ; Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. "Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug." Journal of Clinical Investigation. Vol. 118, no. 7. (July 2008.): 2427-2437.

Blum W, Marcucci G,. "New Approaches in Acute Myeloid Leukemia." Best Practice & Research Clinical Haematology. Vol. 21, no. 1. (March 2008.): 29-41.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang D-S, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen C-S, Byrd JC. "Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia." Journal of Clinical Oncology. Vol. 26, no. 15. (May 2008.): 2519-2525.

Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT. "Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma." Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. Vol. 871, no. 1. (August 2008.): 15-21.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang D-S, Lehman A, Chen C-S, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. "Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells." Blood. Vol. 112, no. 13. (December 2008.): 5180-5189.

Blum W. "Post-remission therapy in acute myeloid leukemia: what should I do now?." Haematologica - The Hematology Journal. Vol. 93, no. 6. (June 2008.): 801-805.

Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation." Biology of Blood and Marrow Transplantation. Vol. 14, no. 7. (July 2008.): 783-789.

Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. "Improved nonrelapse mortaility and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies." Biology of Blood and Marrow Transplantation. Vol. 15, no. 11. (November 2009.): 1422-1430.

Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CEA, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu L-C, Croce CM, Marcucci G. "MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1." Blood. Vol. 113, no. 25. (June 2009.): 6411-6418.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R, Blum W, Grever MR, Marcucci G, Chan KK. "A LC-MS/MS Method for the Analysis of Intracellular Nucleoside Triphosphate Levels." Pharmaceutical Research. Vol. 26, no. 6. (June 2009.): 1504-1515.

Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W. "Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13." Blood. Vol. 113, no. 5. (January 2009.): 1002-1005.

Hamadani M, Benson DM, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. "Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas." Biology of Blood and Marrow Transplantation. Vol. 15, no. 5. (May 2009.): 547-553.

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman John, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias." Journal of Clinical Oncology. Vol. 28, no. 33. (November 2010.): 4919-4925.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Greyer MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias." Haematologica-The Hematology Journal. Vol. 95, no. 7. (July 2010.): 1098-1105.

Blum W. "How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes." Hematology-American Society of Hematology Education Program. Vol. 1, (December 2010.): 314-321.

Schroeder MA, Blum W. "Evidence-Based Mini-Review: Should Patients Over the Age of 60 with INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?." Hematology-American Society of Hematology Education Program. Vol. u, (December 2010.): 322-324.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen C-S, Ford R, Rader C, Muthusamy N, Johnson AJ, Byrd JC. "Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a P13-kinase-dependent pathway." Blood. Vol. 115, no. 13. (April 2010.): 2619-2629.

Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." Proceedings of the National Academy of Sciences of the United States of America. Vol. 107, no. 16. (April 2010.): 7473-7478.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu Y-Z, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "TET2 mutations improve the New European LeukemiaNet risk classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study." Journal of Clinical Oncology. Vol. 29, no. 10. (April 2011.): 1373-1381.

Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM, Blum W, Devine SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." Hematological Oncology. Vol. 29, no. 4. (December 2011.): 202-210.

Blum WG. "Hypomethylating Agents in Myelodysplastic Syndromes." Clinical Advances in Hematology & Oncology : H&O. Vol. 9, no. 2. (February 2011.): 123-.

Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, Williams DA. "RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans." Blood. Vol. 119, no. 20. (May 2012.): 4708-4718.

Yan P, Frankhouser D, Murphy M, Tam H-H, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu Y-Z, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh Ralf, Marcucci G. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia." Blood. Vol. 120, no. 12. (September 2012.): 2466-2474.

Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, Klisovic R, Mims A, Blum W, Marcucci G, Chan KK. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia." Blood. Vol. 119, no. 22. (May 2012.): 5229-5238.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, no. 5. (May 2012.): 1106-1107.

Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld A-K, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci G. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." Blood. Vol. 119, no. 25. (June 2012.): 6025-6031.

Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM. "Acute Lymphoblastic Leukemia." Journal of the National Comprehensive Cancer Network. Vol. 10, no. 7. (July 2012.): 858-913.

Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen C-S, Lee LJ, Jacob S, Mrozek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia." Leukemia. Vol. 27, no. 4. (April 2013.): 871-878.

Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. "Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia." Clinical Cancer Research. Vol. 19, no. 9. (May 2013.): 2355-2367.

Schwind S, Edwards CG, Nicolet D, Mrozek K, Maharry K, Wu Y-Z, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Larson RA, Volinia S, Marcucci G, Bloomfield CD. "inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations." Blood. Vol. 121, no. 2. (January 2013.): 385-391.

Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." Leukemia & Lymphoma. Vol. 54, no. 9. (September 2013.): 1996-2002.

Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia." AAPS Journal. Vol. 15, no. 1. (January 2013.): 242-249.

Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MA. "Toward Personalized Therapy in AML: In Vivo Benefit of Targeting Aberrant Epigenetics in MLL-PTD-Associated AML." Leukemia. Vol. 27, no. 12. (December 2013.): 2379-2382.

Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Munoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, Brook DL, Garman S, Dorrance AM, Zhang X, Zhang J, Lee RJ, Blum W, Caligiuri MA, Marcucci G. "Eradicating Acute Myeloid Leukemia in a Mll(PTD/wt):Flt3(ITD/wt) Murine Model: A Path to Novel Therapeutic Approaches for Human Disease." Blood. Vol. 122, no. 23. (November 2013.): 3778-3783.

Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JP. "Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults." British Journal of Haematology. Vol. 161, no. 3. (May 2013.): 406-410.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu Y-Z, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu L-C, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G. "Lenalidomide-mediated enhanced translation of C/EBP alpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia." Blood. Vol. 121, no. 1. (January 2013.): 159-169.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen C-S, Bittman R, Hokland P, Roy D-C, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D. "PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells." Journal of Clinical Investigation. Vol. 123, no. 10. (October 2013.): 4144-4157.

Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. "Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502." Journal of Clinical Oncology. Vol. 31, no. 7. (March 2013.): 923-929.

Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. "Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)." Haematologica. Vol. 99, no. 1. (January 2014.): 111-115.

Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G. "SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.." Journal of Clinical Investigation. Vol. 124, no. 4. (April 2014.): 1512-1524.

Blum W. "Cancer Immunology, Success Without Sequencing." Journal of the National Comprehensive Cancer Network. Vol. 12, no. 3. (March 2014.): 443-445.

Larkin K, Blum W. "Novel Therapies in AML: Reason for Hope or Just Hype?." American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. Vol. 34, (January 2014.): e341-51.

Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G. "Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia." Leukemia & lymphoma. Vol. 55, no. 6. (June 2014.): 1332-1336.

 

Reference Works

January 2003 Copelan E, Penza S, Lin T, Blum W, Elder P, Ezzone S, Avalos B, Farag S."Results of Allogeneic Transplantation Using Fully Myeloablative Preparation in patients Who Are Candidates for Reduced Intensity Regimens" Washington, DC.
January 2004 Copelan E, Penza S, Lin T, Farag S, Blum W, Elder P, Ezzone S, Avalos B."Matched unrelated transplantation in older individuals" Washington, DC. : 480b
January 2005 Klisovic R, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel JA, Byrd JC, Grever M, Marcucci G."A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results." Washington, DC.
January 2007 Marcucci G, Moser B, Blum W, Stock, Wetzler, Kolitz, Thakuri, Carter, Stuart, Larson."A phase III randomized trial of intensive induction and consolidation chemotherapy+ oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated actue myeloid leukemia patients >60 years old" Chicago.
January 2008 Hamandani M, Blum W, Benson D, Blum K, Porcu P, Elder P, Krugh D, Bechtel T, Andritsos L, Garzon R, Penza S, Lin T, Devine S."Assessment of Rabbit Antithymocyte Globulin (rATG) dose-intensity in patients with hematological malignancies undergoing Allogeneic Stem Cell Transplantation (ASCT) following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATF (FBA)" San Fracisco.
November 2009 Aimiuwu J, Chen P, Xie Z, Liu Z, Liu S, Klisovic R, Blum W, Marcucci G, Chan KK."Development and characterization of 5-Azacytidine resistance in human cancer cell lines" Los Angeles.
November 2011 Lewis C, Heerema NA, Blum W, Whitman J, Hanna J."Culture fibroblasts to determine if abnormalities are constitutional or part of the patient’s disease state" n/a. : 37(3) 192
April 2012 Alice S. Mims, Alison R. Walker, Pia Hoellerbauer, Xiaomeng Huang, Kenneth K. Chan, Rebecca B. Klisovic, Danilo Perrotti, Michael A. Caligiuri, John C. Byrd, Ching-Shih Chen, William Blum, Ramiro Garzon, Sebastian Schwind, and Guido Marcucci."AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML)" Chicago. : abstract 119

Presentations

"Treatment of AML : A comprehensive overview of AML pathophysiology, screening, and diagnostic procedures." Presented at The Ohio State University, Columbus, OH, US|USA. (November 2005)

"Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene re expression, demethylation, and clinical response." Presented at American Society of Clinical Oncology Annual Meeting, Atlanta, GA, US|USA. (June 2006)

"Epigenetic therapy in the treatment of myelodysplastic syndromes." Presented at Cancer Center Grand Rounds, Royal Oaks, MI, US|USA. (December 2006)

"Flavopiridol in acute leukemia: Examples of collaborative use of PK/PD cores & protocol development." Presented at The Ohio State University Pediatric Oncology Program Retreat, Columbus, OH, US|USA. (December 2006)

"Myelodysplastic Syndrome: Exciting new developments in hematology." Presented at OSU CCC, Columbus, OH, US|USA. (May 2006)

"Acute Myeloid Leukemia and Myelodysplastic Syndrome: Recognizing blood cancers in the family practice." Presented at The Ohio State University, Columbus, OH, US|USA. (May 2006)

"Acute Myeloid Leukemia: Recognizing blood cancers in the family practice." Presented at The Ohio State University, Columbus, OH, US|USA. (October 2006)

"Treatment of acute progranulocytic leukemia." Presented at Oncology Nursing Society (ONS) Congress, Las Vegas, NV, US|USA. (April 2007)

"AML in the older adult: disease overview and current research." Presented at Oncology Nursing Society (ONS) Congress, Las Vegas, NV, US|USA. (April 2007)

"AML/MDS update." Presented at Oncology and Hematology 2007 Review and interpretation of the 2007 ASCO, ASH, AACR and other major international meetings, Columbus, OH, US|USA. (June 2007)

"Role of Epigenetic Therapy in AML." Presented at Chemotherapy Symposium XXV, New York, NY, US|USA. (November 2007)

"A comprehensive overview of myelodysplastic syndrome pathophysiology, screening, and diagnostic procedures." Presented at MDS Review, Columbus, OH, US|USA. (March 2007)

"The use of hypomethylating agents in treating aggressive MDS." Indianapolis, IN, US|USA. (March 2007)

"Emerging therapies for MDS." Presented at MDS Conference, Akron, OH, US|USA. (May 2007)

"Challenging Cases in Hematology, Aggressive MDS." Presented at NMCR, Las Vegas, NV, US|USA. (September 2007)

"Epigenetic Therapy in AML: Histone Deacetylase Inhibitors." Presented at Clinical Advances in Epigenetic Therapy Conference, Charleston, SC, US|USA. (September 2007)

"Diagnostic testing in acute leukemia's and other hematologic malignancies: What do I send this for?." Presented at Transplant Nursing Conference, Bone Marrow Transplant Tandem Meeting, Keystone, CO, US|USA. (February 2007)

"Decitabine, a new therapeutic option for MDS." Presented at MDS Conference, Dayton, OH, US|USA. (July 2007)

"CALGB 10503 Update and Future Plans." Presented at CALGB Leukemia Committee Meeting, . (January 2008)

"Myelodysplasia." Presented at American Society of Hematology (ASH) Review, Columbus, OH, US|USA. (January 2008)

"Translational Oncology: Pathways to Future Cancer Therapies." Presented at Network of Oncology Clinicians and Researchers (NOCR) Annual Conference, Las Vegas, NV, US|USA. (March 2008)

"Bortezomib as an Epigenetic Targeting Agent." Presented at Proteasome Inhibitor Combination Trials with Targeted Agents Meeting - National Cancer Institute, Bethesda, MD, US|USA. (April 2008)

"Tanespimycin-Bortezomib Phase I Trial in Leukemia." Presented at Proteasome Inhibitor Combination Trials with Targeted Agents Meeting - National Cancer Institute, Bethesda, MD, US|USA. (April 2008)

"Advances in Management of Myelodysplastic Syndromes." Presented at Grand Rounds, Fort Wayne, IN, US|USA. (September 2008)

"Myelodysplastic Syndromes: An Update from ASH." Presented at American Society of Hematology (ASH) Review, Columbus, OH, US|USA. (January 2008)

"Advances in Management of Myelodysplastic Syndromes." Presented at Grand Rounds, Bowling Green, KY, US|USA. (August 2008)

"Advances in the management of Myelodysplastic Syndromes." Presented at Myelodysplastic Syndromes (MDS) Grand Rounds, Zanesville, Ohio. (December 2008)

"Acute Leukemia." Presented at American Society of Hematology (ASH) Annual Conference Review, Columbus, Ohio. (January 2009)

"CALGB 10503 Update and Future Plans." Presented at CALGB Leukemia Core Committee Meeting, Chicago. (September 2009)

"High-Risk Myelodysplastic Syndromes." Presented at OptumHealth Education Program, Columbus, Ohio. (September 2009)

"Development of a new strategy for treatment of older AML patients." Presented at CALGB Leukemia Core Committee Meeting, Chicago, Illinois. (September 2009)

"Myelodysplastic Syndromes." Presented at OptumHealth Education Program, Lebanon, OH. (March 2009)

"How to get an R21 grant." Presented at American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Florida. (June 2009)

"Remission in older AML patients treated with a novel schedule of Decitabine: miR-29b as a potential predictive marker." Presented at OSUCCC Annual Scientifc Meeting, Columbus, Ohio. (February 2010)

"How Much? How Frequent? How Long? A clinical guide to new therapies in MDS." Presented at 2010 ASH Annual Meeting, Orlando, Florida. (December 2010)

"Acute Myeloid Leukemia - therapy, excluding transplantation: Pediatric and adult AML therapy." Presented at 2010 ASH Annual Meeting, Orlando, Florida. (December 2010)

"Phase I trial of decitabine and bortezomib in AML." Presented at National Cancer Institute Early Drug Development Meeting, Bethesda, Maryland. (September 2010)

"Advances in the management of high-risk AML." Presented at Tumor Board Conference, Atlanta, Georgia. (April 2010)

"R21 Grants, Perseverance, and Resubmission." Presented at Grant Writing Workshop I & II, Chicago, Illinois. (June 2010)

"Leukemia, Myelodysplasia and Transplantation." Presented at ASCO Annual Conference, Chicago, Illinois. (June 2010)

"Leukemia/Myeloma." Presented at ASCO Review, Columbus, Ohio. (June 2010)

"Myelodysplastic Syndromes." Presented at 2011 Highlights of ASH in North America, New York, New York. (February 2011)

"Myelodysplastic Syndromes." Presented at 2011 Highlights of ASH in North America, Vancouver, BC, CA|CAN. (January 2011)

"Blood disorders that cause cytopenias (DDF)." Presented at OSU MedNet 21 CME Webcast, Columbus, Ohio. (July 2011)

"Acute Myeloid Leukemia in Older Adults." Presented at Oncology Drug Advisory Committee (ODAC), Consideration of Dacogen for US FDA Approval in Acute Myeloid Leukemia, Silver Spring, Maryland. (February 2012)

"Myelodysplastic Syndrome and Acute Myeloid Leukemia: an expert discussion panel." Presented at Medscape. Online Programming for Continuing Medical Education, Cleveland, OH, US|USA. (September 2012)

"Novel Therapies in AML." Presented at Hematology Grand Rounds, Houston, Texas. (April 2013)

"Misery and Joy, and Joy and Misery: Clinical Research in Acute Myeloid Leukemia." Presented at Hematology Rounds, Chapel Hill, NC, US|USA. (November 2013)

"Meet the Expert." Presented at American Society of Hematology Annual Meeting 2013, . (December 2013)

"Misery and Joy, and Joy and Misery: Clinical Research in Acute Myeloid Leukemia." Presented at Hematology Rounds, New Haven, CT, US|USA. (February 2014)

"Novel therapies in AML: Hope or hype?." Presented at American Society of Clinical Oncology, Chicago. (May 2014)

 

Professional Activities

2003 - present Spring Relay for Life Kick off Rally. Grove City, OH.
2009 - present NCI Challenge Grants.
2010 - present Multidisciplinary Research Grant. State of North Carolina.
2013 - present Education of Clinical Trials Staff. OSU Clinical Trials Office.
2003 Relay for Life: (summer). American Cancer Society.
2007 Italian Association of Cancer Research.